NLG207 has demonstrated effective targeting of HIF-1α and angiogenesis in models of breast, prostate cancer, and glioblastoma, as monotherapy or in combination with standard therapies, resulting in inhibition of tumor growth and improved animal survival [154,155,156,157]. Here, HIF1A is linked to neoplasm.